This company listing is no longer active
SYAB Stock Overview
Provides clinical laboratory and medical diagnostic services for insurance companies, hospitals, pharmacies, national health organizations, practicing doctors, clinics, patients, governments, and corporations primarily in Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
SYNLAB AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €11.04 |
| 52 Week High | €12.30 |
| 52 Week Low | €8.02 |
| Beta | 0.89 |
| 1 Month Change | 0% |
| 3 Month Change | -0.72% |
| 1 Year Change | 25.53% |
| 3 Year Change | -46.82% |
| 5 Year Change | n/a |
| Change since IPO | -44.03% |
Recent News & Updates
Recent updates
SYNLAB (FRA:SYAB) Might Have The Makings Of A Multi-Bagger
Dec 15
Returns Are Gaining Momentum At SYNLAB (FRA:SYAB)
Sep 10SYNLAB AG (FRA:SYAB) Interim Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Aug 14SYNLAB AG (FRA:SYAB) Stock Catapults 27% Though Its Price And Business Still Lag The Market
May 29SYNLAB (FRA:SYAB) Is Investing Its Capital With Increasing Efficiency
May 20Are Investors Undervaluing SYNLAB AG (FRA:SYAB) By 25%?
Sep 26Shareholders Will Be Pleased With The Quality of SYNLAB's (FRA:SYAB) Earnings
Aug 22Shareholder Returns
| SYAB | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.2% | -0.3% |
| 1Y | 25.5% | 16.5% | 7.0% |
Return vs Industry: SYAB exceeded the German Healthcare industry which returned 4.6% over the past year.
Return vs Market: SYAB exceeded the German Market which returned 6.7% over the past year.
Price Volatility
| SYAB volatility | |
|---|---|
| SYAB Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 4.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: SYAB has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine SYAB's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 27,000 | Mathieu Floreani | www.synlab.com |
SYNLAB AG provides clinical laboratory and medical diagnostic services for insurance companies, hospitals, pharmacies, national health organizations, practicing doctors, clinics, patients, governments, and corporations primarily in Europe. The company offers medical and veterinary diagnostics services. SYNLAB AG was founded in 1998 and is headquartered in Munich, Germany.
SYNLAB AG Fundamentals Summary
| SYAB fundamental statistics | |
|---|---|
| Market cap | €2.43b |
| Earnings (TTM) | €89.35m |
| Revenue (TTM) | €2.62b |
27.2x
P/E Ratio0.9x
P/S RatioIs SYAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SYAB income statement (TTM) | |
|---|---|
| Revenue | €2.62b |
| Cost of Revenue | €604.92m |
| Gross Profit | €2.01b |
| Other Expenses | €1.92b |
| Earnings | €89.35m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Nov 07, 2024
| Earnings per share (EPS) | 0.41 |
| Gross Margin | 76.87% |
| Net Profit Margin | 3.42% |
| Debt/Equity Ratio | 39.0% |
How did SYAB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/09/18 02:41 |
| End of Day Share Price | 2024/07/12 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
SYNLAB AG is covered by 11 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Blanka Porkolab | Barclays |
| Hassan Al-Wakeel | Barclays |
| Charlotte Friedrichs | Berenberg |